Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, Saad F, Shore ND. Freedland SJ, et al. Among authors: rannikko a. NEJM Evid. 2023 Dec;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22. NEJM Evid. 2023. PMID: 38320501 Clinical Trial.
Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.
Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Bruinsma SM, et al. Among authors: rannikko a. Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Nat Rev Urol. 2017. PMID: 28290462 Free article. Review.
Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium. Drost FH, et al. Eur Urol. 2019 Nov;76(5):693-702. doi: 10.1016/j.eururo.2019.07.041. Epub 2019 Aug 24. Eur Urol. 2019. PMID: 31451332
Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma.
Roos-Mattila M, Kallio P, Luck TJ, Polso M, Kumari R, Mikkonen P, Välimäki K, Malmstedt M, Ellonen P, Pellinen T, Heckman CA, Mustonen H, Puolakkainen PA, Alitalo K, Kallioniemi O, Mirtti T, Rannikko AS, Pietiäinen VM, Seppänen HE. Roos-Mattila M, et al. Among authors: rannikko as. Commun Biol. 2024 Oct 20;7(1):1355. doi: 10.1038/s42003-024-07004-9. Commun Biol. 2024. PMID: 39427059 Free PMC article.
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses.
Feodoroff M, Hamdan F, Antignani G, Feola S, Fusciello M, Russo S, Chiaro J, Välimäki K, Pellinen T, Branca RM, Lehtiö J, D Alessio F, Bottega P, Stigzelius V, Sandberg J, Clancy J, Partanen J, Malmstedt M, Rannikko A, Pietiäinen V, Grönholm M, Cerullo V. Feodoroff M, et al. Among authors: rannikko a. Oncoimmunology. 2024 Sep 25;13(1):2407532. doi: 10.1080/2162402X.2024.2407532. eCollection 2024. Oncoimmunology. 2024. PMID: 39351443 Free PMC article.
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry.
Bangma C, Doan P, Zhu L, Remmers S, Nieboer D, Helleman J, Roobol MJ, Sugimoto M, Chung BH, Lee LS, Frydenberg M, Klotz L, Peacock M, Perry A, Bjartell A, Rannikko A, Van Hemelrijck M, Dasgupta P, Moore C, Trock BJ, Pavlovich C, Steyerberg E, Carroll P, Koo KC, Hayen A, Thompson J; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Bangma C, et al. Among authors: rannikko a. Eur Urol Oncol. 2024 Jul 17:S2588-9311(24)00176-7. doi: 10.1016/j.euo.2024.07.003. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39025687 Free article.
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R, Mirtti T, Kilpeläinen TP, Tolonen T, Räisänen-Sokolowski A, Nordling S, Hannus J, Laurila M, Taari K, Tammela TLJ, Autio R, Natunen K, Auvinen A, Rannikko A. Hietikko R, et al. Among authors: rannikko a. World J Urol. 2024 Apr 6;42(1):217. doi: 10.1007/s00345-024-04898-2. World J Urol. 2024. PMID: 38581590 Free PMC article.
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Natunen K, Nevalainen J, Raitanen J, Ronkainen J, van der Kwast T, Riikonen J, Pétas A, Matikainen M, Taari K, Kilpeläinen T, Rannikko AS; ProScreen Trial Investigators. Auvinen A, et al. Among authors: rannikko as. JAMA. 2024 May 7;331(17):1452-1459. doi: 10.1001/jama.2024.3841. JAMA. 2024. PMID: 38581254 Free PMC article. Clinical Trial.
164 results